The development of DPP-4 inhibition as a glucose-lowering principle started in the 1990s with basic studies, continued in the 2000s with clinical studies for introduction of the concept to the market and was further developed in the 2010s with studies in special groups and long-term outcome studies with focus on cardiovascular diseases. The gene discussed is DPP4; the disease is cardiovascular disorder.